Long-Term Opioid Therapy Among Patients With Systemic Lupus Erythematosus in the Community: A Lupus Midwest Network (LUMEN) Study.

Autor:	Figueroa-Parra G; G. Figueroa-Parra, MD, J.Y. Dabit, MD, MS, M.O. Valenzuela-Almada, MD, M. Hocaoglu, MD, S.A. Osei-Onomah, MPH, S. Vallejo, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA., Jeffery MM; M.M. Jeffery, PhD, Division of Health Care Delivery Research, Mayo Clinic, Rochester, Minnesota, USA., Dabit JY; G. Figueroa-Parra, MD, J.Y. Dabit, MD, MS, M.O. Valenzuela-Almada, MD, M. Hocaoglu, MD, S.A. Osei-Onomah, MPH, S. Vallejo, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA., Chevet B; B. Chevet, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA, and Division of Rheumatology, Brest Teaching Hospital, LBAI, UMR1227, Univ Brest, Inserm, CHU de Brest, Brest, France., Valenzuela-Almada MO; G. Figueroa-Parra, MD, J.Y. Dabit, MD, MS, M.O. Valenzuela-Almada, MD, M. Hocaoglu, MD, S.A. Osei-Onomah, MPH, S. Vallejo, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA., Hocaoglu M; G. Figueroa-Parra, MD, J.Y. Dabit, MD, MS, M.O. Valenzuela-Almada, MD, M. Hocaoglu, MD, S.A. Osei-Onomah, MPH, S. Vallejo, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA., Osei-Onomah SA; G. Figueroa-Parra, MD, J.Y. Dabit, MD, MS, M.O. Valenzuela-Almada, MD, M. Hocaoglu, MD, S.A. Osei-Onomah, MPH, S. Vallejo, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA., Kurani S; S. Kurani, PhD, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA., Vallejo S; G. Figueroa-Parra, MD, J.Y. Dabit, MD, MS, M.O. Valenzuela-Almada, MD, M. Hocaoglu, MD, S.A. Osei-Onomah, MPH, S. Vallejo, MD, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA., Achenbach SJ; S.J. Achenbach, MS, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Hooten WM; W.M. Hooten, MD, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA., Barbour KE; K.E. Barbour, PhD, MPH, MS, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Crowson CS; C.S. Crowson, PhD, Division of Rheumatology, Mayo Clinic, and Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Duarte-García A; A. Duarte-García, MD, MSc, Division of Rheumatology, Mayo Clinic, and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA. duarte.ali@mayo.edu.
Jazyk:	angličtina
Zdroj:	The Journal of rheumatology [J Rheumatol] 2023 Apr; Vol. 50 (4), pp. 504-511. Date of Electronic Publication: 2022 Nov 15.
DOI:	10.3899/jrheum.220822
Abstrakt:	Objective: There is little information about the epidemiology and factors associated with opioid therapy in systemic lupus erythematosus (SLE). We aimed to assess the prevalence of opioid therapy and explore factors associated with long-term opioid therapy (LTOT) in patients with SLE. Methods: Patients with SLE were matched with controls without SLE in a population-based cohort on January 1, 2015. We captured demographics, manifestations of SLE, comorbidities (ie, fibromyalgia, mood disorders, osteoarthritis, chronic low back pain [CLBP], chronic kidney disease (CKD), avascular necrosis, osteoporosis, fragility fractures, and cancer), and the Area Deprivation Index (ADI). Opioid prescription data were used to assess the prevalence of LTOT, defined as contiguous prescriptions (gaps of < 30 days between prescriptions) and receiving opioid therapy for ≥ 90 days or ≥ 10 prescriptions before the index date. Results: A total of 465 patients with SLE and 465 controls without SLE were included. In total, 13% of patients with SLE and 3% of controls without SLE were receiving opioid therapy ( P < 0.001), and 11% of patients with SLE were on LTOT vs 1% of controls without SLE. Among patients with SLE, acute pericarditis (odds ratio [OR] 3.92, 95% CI 1.78-8.66), fibromyalgia (OR 7.78, 95% CI 3.89-15.55), fragility fractures (OR 3.72, 95% CI 1.25-11.07), CLBP (OR 4.00, 95% CI 2.13-7.51), and mood disorders (OR 2.76, 95% CI 1.47-5.16) were associated with LTOT. We did not find an association between opioid therapy and ADI. Conclusion: Patients with SLE are more likely to receive LTOT than controls. Among patients with SLE, LTOT was associated with pericarditis and several comorbidities. However, LTOT was not associated with CKD despite the limited pain control options among these patients. (Copyright © 2023 by the Journal of Rheumatology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu